Loading...
Market
What will be the performance outcome of Jnana Therapeutics' RAPID platform under Otsuka's ownership by December 31, 2024?
2
Resolution / Starting Odds
Significant advancements in PKU treatment • 25%
Significant advancements in autoimmune disease research • 25%
No significant advancements • 25%
Other • 25%
Official press releases from Jnana Therapeutics or Otsuka Pharmaceutical, scientific publications
Story
Otsuka Pharmaceutical to Acquire Boston-based Jnana Therapeutics for Up to $1.1 Billion
Aug 1, 2024, 05:26 AM
Japan's Otsuka Pharmaceutical announced on Thursday that it will acquire U.S.-based Jnana Therapeutics for up to $1.1 billion. The deal includes an upfront payment of $800 million and potential milestone payments of up to $325 million. Jnana Therapeutics, based in Boston, is known for its RAPID platform and the investigational drug JNT-517, which has shown effectiveness in treating phenylketonuria (PKU) in Phase 1b/2 trials. Following the acquisition, Jnana will operate as a subsidiary of Otsuka in Boston, continuing its research and development efforts. PKU is a rare inherited metabolic disorder characterized by high levels of phenylalanine in the blood. Jnana's CEO and co-founder is Joanne Kotz, and the company is also involved in research related to autoimmune diseases.
View original story
Similar markets
Autoimmune diseases • 25%
Neurological disorders • 25%
Metabolic disorders • 25%
Other therapeutic areas • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Joanne Kotz remains CEO • 25%
New CEO appointed from Otsuka • 25%
New CEO appointed externally • 25%
Other leadership changes • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
New Phase 3 trial initiated • 25%
Govorestat approval without new trial • 25%
Govorestat development halted • 25%
Partnership or acquisition for Govorestat • 25%
Positive • 25%
Negative • 25%
Neutral • 25%
Not Reported • 25%